Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EBS stock price vs EPD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EPD's multiple
Needs EPD P/E.
Implied fair value · at EBS's multiple
Needs EBS P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EBS FY 2025 (ended Dec 31, 2025) · EPD FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 35% equity / 65% debt · EV / Revenue 0.95x · EV / EBITDA 2.95x
Capital structure 71% equity / 29% debt · EV / Revenue 2.23x · EV / EBITDA 12.25x
EPD carries the larger enterprise value at $117.52B against $703.22M; EBS trades on the lower EV / Revenue multiple (0.95x vs 2.23x); EBS on the lower EV / EBITDA (2.95x vs 12.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EMERGENT BIOSOLUTIONS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ENTERPRISE PRODUCTS PARTNERS L.P. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.13x
—
Net debt / EBITDA
Leverage against operating earnings
1.61x
3.48x
Cash and equivalents
Liquid reserves on the balance sheet
$205.40M
$969.00M
Total debt
Interest-bearing obligations outstanding
$589.70M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
EBS vs MRNA
SIGA TECHNOLOGIES INC
EBS vs SIGA
Amphastar Pharmaceuticals, Inc.
EBS vs AMPH
CATALYST PHARMACEUTICALS, INC.
EBS vs CPRX
Organon & Co.
EBS vs OGN
PERRIGO Co plc
EBS vs PRGO
WILLIAMS COMPANIES, INC.
EBS vs WMB
ONEOK INC /NEW/
EBS vs OKE
Energy Transfer LP
EBS vs ET
KINDER MORGAN, INC.
EBS vs KMI
Targa Resources Corp.
EBS vs TRGP
$34.40B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
